Cancer immunotherapy articles within Nature

Featured

  • Article
    | Open Access

    The transcription factor FOXO1 has a key role in human T cell memory, and manipulating FOXO1 expression could provide a way to enhance CAR T cell therapies by increasing CAR T cell persistence and antitumour activity.

    • Alexander E. Doan
    • , Katherine P. Mueller
    •  & Evan W. Weber

  • Article
    | Open Access

    Peptide-centric chimeric antigen receptors (PC-CARs) provide a platform to address the challenges involved in targeting intracellular oncoproteins, and PC-CARs based on the neuroblastoma-dependency gene PHOX2B induce elimination of aggressive tumors.

    • Mark Yarmarkovich
    • , Quinlen F. Marshall
    •  & John M. Maris

  • Article |

    Genomics analyses reveal that in vitro culture of CAR T cells can lead to reactivation of a latent herpesvirus, which might be involved in complications in patients receiving associated cell therapies.

    • Caleb A. Lareau
    • , Yajie Yin
    •  & Ansuman T. Satpathy

  • Article
    | Open Access

    An orally bioavailable small-molecule active-site inhibitor of the phosphatases PTPN2 and PTPN1, ABBV-CLS-484, demonstrates immunotherapeutic efficacy in mouse models of cancer resistant to PD-1 blockade.

    • Christina K. Baumgartner
    • , Hakimeh Ebrahimi-Nik
    •  & Robert T. Manguso

  • Article |

    A CRISPR–Cas9 screen in a tumour mouse model identifies CD300ld as a tumour receptor on polymorphonuclear myeloid-derived suppressor cells and in vivo experiments indicate that it is a promising target for cancer immunotherapy.

    • Chaoxiong Wang
    • , Xichen Zheng
    •  & Min Luo

  • Perspective |

    This Perspective reviews advances in the understanding of the intersection between the DNA damage response and the response to immune checkpoint blockade therapy, and discusses how developments in the field could lead to improved anti-cancer therapies.

    • Anand V. R. Kornepati
    • , Cody M. Rogers
    •  & Tyler J. Curiel

  • Article
    | Open Access

    A phase I clinical trial of an adjuvant personalized mRNA neoantigen vaccine, autogene cevumeran, in patients with pancreatic ductal carcinoma demonstrates that the vaccine can induce T cell activity that may correlate with delayed recurrence of disease.

    • Luis A. Rojas
    • , Zachary Sethna
    •  & Vinod P. Balachandran

  • Article |

    Logic gating is used to develop a CAR T cell platform that is highly specific and allows the activity of T cells to be restricted to the encounter of two antigens, thus reducing on-target, off-tumour toxicity.

    • Aidan M. Tousley
    • , Maria Caterina Rotiroti
    •  & Robbie G. Majzner

  • Article
    | Open Access

    Patients with resectable clinical stage III or oligometastatic stage IV melanoma were given neoadjuvant relatlimab and nivolumab combination immunotherapy, which induced a high pathologic complete response rate, indicating the efficacy and safety of this regimen.

    • Rodabe N. Amaria
    • , Michael Postow
    •  & Hussein A. Tawbi

  • Article
    | Open Access

    Binding of the PD1-IL2v immunocytokine to PD-1 and IL-2Rβγ on the same cell leads to an alternative differentiation of stem-like CD8+ T cells into better effectors rather than exhausted T cells in models of both chronic infection and cancer.

    • Laura Codarri Deak
    • , Valeria Nicolini
    •  & Pablo Umaña

  • Article |

    A small molecule can bypass the RNA-editing enzyme ADAR1 to directly activate the Z-form nucleic acid sensor ZBP1, induce necroptosis in tumour fibroblasts and reverse resistance to immune checkpoint blockade in mouse models of melanoma.

    • Ting Zhang
    • , Chaoran Yin
    •  & Siddharth Balachandran

  • Article |

    Inhibiting the PCSK9 protein, a regulator of cholesterol metabolism, enhances immune checkpoint therapy in mouse models of cancer, in a manner that depends on the regulation of antigen-presenting MHC I molecules.

    • Xinjian Liu
    • , Xuhui Bao
    •  & Chuan-Yuan Li

  • Article |

    Results of an exploratory interim analysis from a phase I trial show that an RNA vaccine targeted towards four melanoma-associated antigens produces durable objective responses in patients with melanoma that are accompanied by strong CD4+ and CD8+ T-cell immunity.

    • Ugur Sahin
    • , Petra Oehm
    •  & Özlem Türeci

  • Article |

    Large-scale single-cell sequencing of RNA and T cell receptors in samples from patients with cancer shows clonotypic expansion of effector-like T cells not only in tumour tissue but also in normal adjacent tissues and peripheral blood, which associates with clinical response to cancer immunotherapy.

    • Thomas D. Wu
    • , Shravan Madireddi
    •  & Jane L. Grogan

  • Article |

    Multiomic profiling of several cohorts of patients treated with immune checkpoint blockade highlights the presence and potential role of B cells and tertiary lymphoid structures in promoting therapy response.

    • Beth A. Helmink
    • , Sangeetha M. Reddy
    •  & Jennifer A. Wargo

  • Article |

    Immune profiling of the tumour microenvironment of soft-tissue sarcoma identifies a group of patients with high levels of B-cell infiltration and tertiary lymphoid structures that have improved survival and a high response rate to immune checkpoint blockade therapy.

    • Florent Petitprez
    • , Aurélien de Reyniès
    •  & Wolf H. Fridman

  • Review Article |

    The authors review recent developments in our understanding of the antitumour effects of the innate immune system and how this system could be harnessed in the clinic.

    • Olivier Demaria
    • , Stéphanie Cornen
    •  & Eric Vivier

  • Letter |

    Transfer of NR4A-deficient T cells expressing chimeric antigen receptors is shown to reduce tumour burden and increase survival by shifting T cell transcriptional programs away from exhaustion and towards increased effector function.

    • Joyce Chen
    • , Isaac F. López-Moyado
    •  & Anjana Rao

  • Article |

    A hyper-stable de novo protein mimic of interleukin-2 computationally designed to not interact with a regulatory T-cell specific receptor subunit has improved therapeutic activity in mouse models of melanoma and colon cancer.

    • Daniel-Adriano Silva
    • , Shawn Yu
    •  & David Baker

  • Letter |

    A non-viral strategy to introduce large DNA sequences into T cells enables the correction of a pathogenic mutation that causes autoimmunity, and the replacement of an endogenous T-cell receptor with an engineered receptor that can recognize cancer antigens.

    • Theodore L. Roth
    • , Cristina Puig-Saus
    •  & Alexander Marson

  • Letter |

    An immune fitness model for tumours under checkpoint blockade immunotherapy is proposed, through which the authors show that the presentation and recognition properties of dominant neoantigens distributed over tumour subclones are predictive of response in melanoma and lung cancer cohorts.

    • Marta Łuksza
    • , Nadeem Riaz
    •  & Benjamin D. Greenbaum

  • Letter |

    Introducing chimeric antigen receptors into the endogenous T-cell receptor locus reduces tonic signalling, averts accelerated T-cell differentiation and delays T-cell exhaustion, leading to enhanced function and anti-tumour efficacy compared to random integrations.

    • Justin Eyquem
    • , Jorge Mansilla-Soto
    •  & Michel Sadelain

  • Letter |

    The development of a nanoparticle RNA vaccine is reported that preferentially targets dendritic cells after systemic administration, and is shown to provide durable interferon-α-dependent antigen-specific immunity in mouse tumour models; initial results in advanced melanoma patients indicate potential efficacy in humans.

    • Lena M. Kranz
    • , Mustafa Diken
    •  & Ugur Sahin

  • Letter |

    The authors show that a large fraction of tumour mutations is immunogenic and predominantly recognized by CD4+ T cells; they use these data to design synthetic messenger-RNA-based vaccines specific against tumour mutations, and show that these can reject tumours in mice.

    • Sebastian Kreiter
    • , Mathias Vormehr
    •  & Ugur Sahin

  • Outlook |

    Increased understanding of immune- and tumour-cell biology has led to an explosion of research into potential ways to harness the immune system to kill cancer. By Emily Elert.

    • Emily Elert

  • Outlook |

    William Coley found a way to prompt the immune system to fight cancer over a century ago. After years of neglect, scientists are now seeking to replicate his success.

    • Sarah DeWeerdt

  • Outlook |

    An experimental vaccine implanted beneath the skin could usher in biomaterial-based immunotherapies for cancer.

    • Elie Dolgin

  • Outlook |

    Immunologist Karolina Palucka, at the Baylor Institute for Immunology Research in Dallas, Texas, helped treat Nobel prizewinner Ralph Steinman's pancreatic cancer with dendritic cells — the cells he co-discovered. Here she explains the use of dendritic cells in cancer immunotherapy.

    • Karolina Palucka

  • Outlook |

    Using a variety of creative imaging techniques, researchers are tracking the dynamic interactions of immune and cancer cells. Their results will guide drug development.

    • Katherine Bourzac

Browse broader subjects

Browse Cancer immunotherapy across other nature.com journals